Filing Flows › Ligand Pharmaceuticals (LGND) › Guidance history
Ligand Pharmaceuticals (LGND) guidance history: what it guided and what it reported
Ligand Pharmaceuticals gave guidance in 12 earnings releases on file since Nov 8, 2023. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +26.8% against the guided midpoint. Its releases raised guidance 6 times and lowered it twice.
Revenue
Met or beat 2 of 2 periods (2 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $245M–$285M (Feb 26, 2026) → raised $270M–$310M (Oct 29, 2026) | — | to be reported | — |
| FY2025 | $180M–$200M (Feb 27, 2025) → reaffirmed $180M–$200M (May 8, 2025) | $268M | above the range | +41.1% |
| FY2024 | $130M–$142M (Feb 27, 2024) → reaffirmed $130M–$142M (May 7, 2024) → raised $140M–$157M (Aug 6, 2024) | $167M | above the range | +12.6% |
Adjusted revenue
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $180M–$200M (Feb 27, 2025) → reaffirmed $180M–$200M (May 8, 2025) | — | — | — |
| FY2024 | $130M–$142M (Feb 27, 2024) → reaffirmed $130M–$142M (May 7, 2024) | — | — | — |
GAAP net income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $107M (Aug 6, 2026) | — | to be reported | — |
Adjusted net income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $195M (Aug 6, 2026) | — | to be reported | — |
Stock-based compensation
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $57.0M (Aug 6, 2026) | — | to be reported | — |
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $8.00–$9.00 (Feb 26, 2026) → raised $8.50–$9.50 (May 7, 2026) → raised $9.00–$9.50 (Aug 6, 2026) → raised $9.50–$9.75 (Oct 29, 2026) | — | to be reported | — |
| FY2025 | $2.00 (Feb 27, 2025) → raised $6.00–$6.25 (May 8, 2025) → lowered $1.00–$6.70 (Aug 7, 2025) | — | — | — |
The latest quarter
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Questions
Does Ligand Pharmaceuticals beat its guidance?
Ligand Pharmaceuticals gave guidance in 12 earnings releases on file since Nov 8, 2023. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +26.8% against the guided midpoint.
How often does Ligand Pharmaceuticals raise guidance?
Its earnings releases raised guidance 6 times and lowered it twice since Nov 8, 2023.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.